SPONSOR
Lepu Biopharma Co., Ltd.
Total Trials
2
Recruiting
2
Phases
Phase 3, Phase 1, Phase 2
Lepu Biopharma Co., Ltd. is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Recurrent or Metastatic Nasopharyngeal Carcinoma, Hepatocellular Carcinoma.
The trial portfolio spans Phase 3, Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Lepu Biopharma Co., Ltd.
How many clinical trials has Lepu Biopharma Co., Ltd. sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by Lepu Biopharma Co., Ltd., of which 2 are actively recruiting participants. These trials cover conditions including Recurrent or Metastatic Nasopharyngeal Carcinoma, Hepatocellular Carcinoma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Lepu Biopharma Co., Ltd. research focus on?
Lepu Biopharma Co., Ltd. clinical trials span Recurrent or Metastatic Nasopharyngeal Carcinoma, Hepatocellular Carcinoma. The research pipeline includes Phase 3, Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Lepu Biopharma Co., Ltd. clinical trial?
To participate in a Lepu Biopharma Co., Ltd. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Lepu Biopharma Co., Ltd. trials with current recruitment status updated daily.
Clinical Trials by Lepu Biopharma Co., Ltd.
NCT06976190 Phase 3
Recruiting
A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
Recurrent or Metastatic Nasopharyngeal Carcinoma
NCT07479485 Phase 1, Phase 2
Recruiting
MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
Hepatocellular Carcinoma
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology